Nadia Lelutiu

TL;DR: A good deal of effort has been expended to determine whether COX‐2 inhibition might be neuroprotective and represent an adjunct therapeutic strategy along with antiepileptic drugs used to treat epilepsy, however, the effectiveness of COx‐2 inhibitors on epilepsy animal models appears to depend on the timing of administration.

TL;DR: In this article, the effects of rapid activity-triggered induction of COX-2 in neurons have been the subject of much study and speculation and to address this issue directly, they created a mouse in which COX2 is conditionally ablated in selected forebrain neurons.

TL;DR: Results following pilocarpine-induced status epilepticus indicate that seizure-induced neuronal COX-2 expression in neurons promotes early neuroprotection and then delayed neurodegeneration of CA1 pyramidal neurons, and is essential for development of a leaky blood–brain barrier after seizures.

TL;DR: A suite of small molecules with a 3-aryl-acrylamide scaffold as selective EP2 antagonists raise the possibility that selective block of EP2 signaling via small molecules can be an innovative therapeutic strategy for inflammation-related brain injury.

TL;DR: A review examines ZikV strain differences from an evolutionary perspective, discussing how these differentially impact pathogenesis via host immune responses that modulate IFN signaling, and how these differential effects dictate the future of ZIKV vaccine candidates.